Authoritative, in-depth and practical financial information is here
The heat of the “anti Helicobacter pylori concept” did not decrease, and the leading stocks Zhejiang Yatai Pharmaceutical Co.Ltd(002370) ushered in the fifth consecutive daily limit on January 12.
Shareholders can’t sit still.
Zhejiang Yatai Pharmaceutical Co.Ltd(002370) announced on January 11 that the shareholder Bank Of Ningbo Co.Ltd(002142) holding 7.27% intends to empty its 39 million shares and transfer them to Fubang group, the largest shareholder, at a transaction price of 5.21 yuan / share and a total transfer price of 203 million yuan.
After the completion of the transaction, Bank Of Ningbo Co.Ltd(002142) will no longer hold shares in the company, and the shareholding ratio of Fubang group and its concerted actors will rise to 18.02%.
interestingly, Fubon group is one of the main shareholders of Bank Of Ningbo Co.Ltd(002142) and the sixth largest shareholder of the latter.
Compared with the latest share price of 7.7 yuan / share, Bank Of Ningbo Co.Ltd(002142) has a “discount” of about 32% and a greater “discount”. However, looking back at the K-line chart of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) in recent two years, the company’s share price hovered below 5 yuan for a long time, and fell to about 3 yuan in January 2021.
For Bank Of Ningbo Co.Ltd(002142) with “passive entry”, this transaction is a “good deal”.
In June 2021, Bank Of Ningbo Co.Ltd(002142) as a creditor, transferred 25 million shares under the name of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) shareholder Chen Yaogen and 14 million shares under the name of Zhong Wanzhen to offset the debt owed by the two people of about 160 million yuan, and the shareholding ratio increased to 7.27%. Therefore, it is estimated that the holding cost of Bank Of Ningbo Co.Ltd(002142) is about 4 yuan / share.
With the continuous performance of judicial auction, Zhejiang Yatai Pharmaceutical Co.Ltd(002370) share price was depressed, and suddenly ushered in a sharp rise at the beginning of this year. Since the beginning of 2022, its share price has increased by 72%.
The reason driving the continuous rise of stock prices is the news that “Helicobacter pylori is listed as a clear carcinogen in the United States”. On the interactive platform, in the face of investors\’ questions about anti Helicobacter pylori, the company also “took the trouble” to give positive replies.
For Bank Of Ningbo Co.Ltd(002142) , about 30% of the proceeds can be obtained from the sale of shares at fenggao. “For financial institutions, what they pursue is not profit maximization, but steady income.” Investment bankers told reporters, “from another perspective, the remaining problems of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) have not been cleared up, and the fundamentals have not been improved. It is a wise choice to stop at a good time.”
For the transferee Fubon group, this transaction is of strategic significance. As a “Hunter”, Fubang group acted in unison, and human Hangui investment has been lurking for a long time. Since July 2021, Fubon group and its allies have participated in Zhejiang Yatai Pharmaceutical Co.Ltd(002370) judicial auctions for many times, successively pocketing more than 10% of its shares at a cost of more than 200 million yuan. In addition, Fubon group also increased its holdings of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) 0.68% through the secondary market.
After the continuous overweight of “two-line operation”, Fubang group has held 10.75% of the shares of the listed company, becoming the largest shareholder.
According to the retrospective data, Chen Yaogen and Zhong Wanzhen, the former actual controllers of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) , were sued by many financial institutions due to loan disputes, and their shares in listed companies were continuously “divided”, resulting in the decentralization of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) equity structure. In November 2021, Zhejiang Yatai Pharmaceutical Co.Ltd(002370) announced that due to the dispersion of equity, the company changed to the state of no actual controller.
Statistics show that Fubang group is a private enterprise in Ningbo with a registered capital of 270 million yuan. It is a comprehensive large-scale enterprise group with industry as the main body and integrating commerce and trade, real estate, energy, scientific research, hotel services, financial investment and sports culture. It has entered the ranks of “top 500 Chinese enterprises” for many consecutive years. The actual controller of the company is song Han equality management team, and there is another old listed company Ningbo Fubang Jingye Group Co.Ltd(600768) . According to the financial report data, Fubang group had total assets of RMB 21.9 billion by the end of 2020, achieved revenue of about RMB 9.1 billion and net profit of RMB 554 million in 2020.
In the latest detailed equity change report, Fubon group made it clear that it seeks to be the controlling shareholder of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) .
Back to the fundamentals of Zhejiang Yatai Pharmaceutical Co.Ltd(002370) , it is still difficult to be optimistic. In 2019, Zhejiang Yatai Pharmaceutical Co.Ltd(002370) suffered a loss of 1.9 billion yuan due to factors such as financial fraud, out of control and illegal guarantee of subsidiaries; It will recover in 2020, with a profit of 27.27 million yuan; In the first three quarters of 2021, the company’s revenue decreased by 39.5% year-on-year and lost 95.11 million yuan. In November 2021, new century downgraded Zhejiang Yatai Pharmaceutical Co.Ltd(002370) credit rating from BB to B.
